Filters
Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.
Men who are exposed to air pollution may experience changes in genes that are relevant to sperm development, potentially affecting fertility, pregnancy outcomes, and even offspring health, suggests a recent study.
For a carefully selected group of patients with medically refractory, lung-limited, stage IV non-small cell lung cancer (NSCLC), bilateral lung transplant appears beneficial, being associated with favourable early survival outcomes, as shown in a study.
The use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with obstructive sleep apnoea (OSA) may reduce the incidence of cerebrovascular events, minimize healthcare use, and lower all-cause mortality, according to a retrospective study.
Daily supplementation with multivitamins offers no significant protection against the incidence of COVID-19 in older adults when compared with placebo, as shown in the COSMOS randomized trial.
The use of leukotriene receptor antagonists (LTRAs), especially when combined with H1 antihistamines (H1AHs), can lower the risk of lung cancer in patients with asthma or allergic rhinitis, suggests a study.
In patients with chronic obstructive pulmonary disease (COPD), acute exacerbations contribute to an increased risk of cardiopulmonary complications, as shown in a retrospective cohort study.
Cardiac rehabilitation produces functional capacity gains and quality of life improvements in patients with coronary heart disease (CHD), and a history of COVID-19 does not blunt this effect, according to a study.
Patients with asthma and chronic obstructive pulmonary disease (COPD) appear to have an elevated risk of pertussis infection, according to the results of a systematic review and meta-analysis.
Proximal hypoglossal nerve stimulation (pHGNS) delivers durable improvements in patients with obstructive sleep apnoea (OSA) in the phase III THN*3 trial.